Bavarian Nordic cans respiratory vaccine

Bavarian Nordic today announced that the phase 3 Vanir trial of its adult respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV, did not meet all the primary endpoints of preventing lower respiratory tract disease (LRTD).